首页|硝唑尼特改善西方饮食诱导的ApoE-/-小鼠脂肪肝作用的代谢组学研究

硝唑尼特改善西方饮食诱导的ApoE-/-小鼠脂肪肝作用的代谢组学研究

扫码查看
硝唑尼特(nitazoxanide)是一种临床抗原虫药物,本课题组前期研究发现口服途径给予硝唑尼特可改善西方饮食(Western diet,WD)诱导的ApoE-/-小鼠肝脏脂肪样变,尚待深入阐明其机制。本文通过非靶向代谢组学研究硝唑尼特对西方饮食诱导的ApoE-/-小鼠肝脏代谢谱的影响,进而通过细胞水平实验研究其潜在机制。采用UPLC-MS联用法对小鼠的肝脏组织代谢物进行非靶向代谢组学研究;筛选差异代谢物,并对差异代谢物进行富集分析和通路分析;采用硝唑尼特的体内代谢产物替唑尼特处理肝细胞,在代谢组学发现的基础上研究硝唑尼特改善肝脏脂代谢异常的潜在机制。硝唑尼特改善西方饮食诱导的ApoE-/-小鼠肝脏代谢紊乱,主要通过调控甘油磷脂代谢、D-谷氨酰胺和谷氨酸代谢、谷胱甘肽代谢和精氨酸生物合成。硝唑尼特的体内活性代谢产物替唑尼特(tizoxanide)增加HepG2细胞谷胱甘肽(glutathione,GSH)含量并促进谷氨酸半胱氨酸连接酶(glutamate-cysteine ligase catalytic subunit,Gcl-c)和谷胱甘肽还原酶(glutathione reductase,Gsr)的mRNA表达;增加肝细胞胱硫醚β合酶(cystathionine β-synthase,CBS)和磷脂酰乙醇胺N-甲基转移酶(phosphatidylethanolamine N-methyltransferase,PEMT)蛋白水平,抑制游离脂肪酸(free fatty acid,FFA)诱导的肝细胞脂质蓄积;替唑尼特可增加FFA刺激下HepG2细胞及小鼠原代肝细胞中S-腺苷同型半胱氨酸水解酶(S-adenosyl-L-homocysteine hydrolase,SAHH)蛋白表达;替唑尼特提高HepG2细胞N-乙酰谷氨酸合酶(N-acetyl glutamate synthase,Nags)和氨基甲酰磷酸合成酶1(carbamoylphosphate synthetase 1,Cps1)mRNA表达水平。综上所述,硝唑尼特改善西方饮食诱导的ApoE-/-小鼠肝脏脂肪样变的潜在机制包括增加CBS表达、提高肝细胞内谷胱甘肽含量,增加肝细胞PEMT蛋白水平,增加肝细胞Nags和Cps1的表达。
Metabolomic study of the improvement of nitazoxanide on Western-diet induced hepatic steatosis in ApoE-/-mice
Nitazoxanide is an FDA-approved antiprotozoal drug.Our previous study found that oral administration of nitazoxanide inhibited Western diet(WD)-induced hepatic steatosis in ApoE-/-mice.However,the specific mechanism remains to be elucidated.In the present study,we performed an untargeted metabolomics approach to reveal the effect of nitazoxanide on the liver metabolic profiles in WD-fed ApoE-/-mice,and carried out the cellular experiments to elucidate the underlying mechanisms.UPLC-MS-based untargeted metabolomics analysis was used to investigate the effect of nitazoxanide on global metabolite changes in liver tissues.The differential metabolites were screened for enrichment analysis and pathway analysis.Hepatocytes were treated with tizoxanide,the metabolite of nitazoxanide,to investigate the underlying mechanism based on the findings in metabolomics study.The improvement of liver lipid metabolism disorders by nitazoxanide treatment in WD-fed ApoE-/-mice was mainly through regulating glycerophospholipid metabolism,D-glutamine and glutamate metabolism,glutathione metabolism,and arginine biosynthesis metabolism.Tizoxanide,the active metabolite of nitazoxanide,increased glutathione(GSH)contents and glutamate-cysteine ligase catalytic subunit(Gcl-c)and glutathione reductase(Gsr)mRNA expressions in HepG2 cells.Tizoxanide increased cystathionine β-synthase(CBS)and phosphatidylethanolamine N-methyltransferase(PEMT)protein levels,inhibited lipid accumulation in hepatocytes induced by free fatty acid(FFA).Tizoxanide increased S-adenosyl-L-homocysteine hydrolase(SAHH)protein levels in HepG2 cells and mouse primary liver cells stimulated with free fatty acid(FFA).Tizoxanide increased N-acetyl glutamate synthase(Nags)and carbamoylphosphate synthetase 1(Cps1)mRNA expressions in HepG2 cells.In conclusion,nitazoxanide improves WD-induced hepatic steatosis in ApoE-/-mice and the underlying mechanisms include increasing CBS expression,GSH content,PEMT protein expression,Nags and Cps1 mRNA expression in hepatocytes.

nitazoxanidetizoxanidenon-alcoholic fatty liver diseasemetabolomicsglutathione

朱胡太龙、程晓范、郭欣、常乐、赵银娣、吴尚泽、董德利

展开 >

中国药科大学药学院,江苏南京 211198

杭州联川生物技术股份有限公司,浙江杭州 310018

硝唑尼特 替唑尼特 非酒精性脂肪肝 代谢组学 谷胱甘肽

2024

药学学报
中国药学会 中国医学科学院药物研究所

药学学报

CSTPCD北大核心
影响因子:1.274
ISSN:0513-4870
年,卷(期):2024.59(9)